Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
The growing demand for early and precise disease diagnosis has made biomarker detection a vital component of modern precision medicine. However, conventional detection methods often struggle with cost, scalability, and robustness in complex biological samples. Molecularly imprinted polymers (MIPs), synthetic biorecognition materials that mimic natural molecular recognition mechanisms, have emerged as a transformative solution and gained increasing attention from the scientific community. MIPs are created by forming specific recognition sites within the polymer matrix using target molecules as templates. These sites enable MIPs to recognize the target molecules with high sensitivity and specificity, making them highly promising for applications in biomarker detection. The aim of this review is to comprehensively summarize the latest research on the application of MIPs in clinical diagnostic biomarker assays from 2021 to 2025, with a particular focus on (1) composition and structure of MIPs; (2) preparation methods; and (3) the use of MIPs for biomarker detection. Through an in-depth analysis of these studies, this review endeavors to provide valuable insights and guidance for future medical research and clinical applications involving MIPs.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00604-025-07443-z | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Patient and Physician Perceptions of Prostate-Specific Antigen Testing Among Black Individuals.
JAMA Netw Open
September 2025
Department of Urology, Center for Health Outcomes Research and Dissemination, University of Washington, Seattle.
Importance: Black individuals have a twofold higher rate of prostate cancer death in the US compared with the average population with prostate cancer. Few guidelines support race-conscious screening practices among at-risk Black individuals.
Objective: To examine structural factors that facilitate or impede access to prostate cancer screening among Black individuals in the US.
Accounting for endoscopic screening in colorectal cancer risk models.
Cancer Epidemiol Biomarkers Prev
September 2025
Brigham and Women's Hospital, Boston, MA, United States.
Background: Colorectal cancer (CRC) risk models routinely adjust for endoscopic screening because of a) possible confounding with other risk factors and b) possible alteration of natural history of the disease due to adenoma detection and removal.
Methods: In this study, we defined a subject as screen-covered (SC) if a colonoscopy was performed in the past 10 years, and not screen-covered (NSC) otherwise. We created CRC risk models separately for SC and NSC subjects (HRSC, HRNSC) and then obtained a screening-coverage adjusted HR estimate (HRfull) based on a weighted average of ln(HRSC) and ln(HRNSC) with weight equal to the proportion of SC person-time in the NHS population.
Concentration and integrity index of circulating cell-free DNA as a biomarker in pediatric patients with B-ALL.
Cell Mol Biol (Noisy-le-grand)
September 2025
Doctorado en Genética Humana, Centro Universitario de Ciencias de la Salud. Universidad de Guadalajara, Jalisco, México.
The objective of this study was to evaluate the concentration and integrity index of circulating cell-free DNA (ccf-DNA) as biomarkers for the detection and monitoring of minimal residual disease (MRD) in pediatric patients with B-cell acute lymphoblastic leukemia (B-ALL). Comparison with a validated methodology for the quantification of monoclonal rearrangements of the IGH gene was made. Peripheral blood and bone marrow samples were collected from 10 pediatric patients with B-ALL at diagnosis, remission, and maintenance phases.
View Article and Find Full Text PDFA Rapid Electrochemical Immunosensor Platform for the Sepsis-Associated Host and Pathogen Marker Dual Detection.
Langmuir
September 2025
Centre for Biomedical Engineering, Indian Institute of Technology, Delhi, New Delhi 110016, India.
The study addresses the critical issue of sepsis diagnosis, a life-threatening condition triggered by the body's immune response to infection that leads to mortality. Current diagnostic methods rely on the time-consuming assessment of multiple biomarkers by a series of tests, leading to delayed treatment. Here, we report a platform for developing a point-of-care (POC) device utilizing electrochemical immunosensors for the dual and rapid detection of sepsis biomarkers: Procalcitonin (PCT), Interleukin-6 (IL-6), and C-reactive protein (CRP) as host markers and lipopolysaccharide (LPS) as a pathogen marker.
View Article and Find Full Text PDFThe International Association for the Study of Lung Cancer Staging Project: The Impact of Common Molecular Alterations on Overall Survival in NSCLC in Initial Analyses of the IASLC Ninth Edition Staging Database.
J Thorac Oncol
July 2025
Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
Introduction: TNM staging systems create prognostic categories by anatomic extent of disease. Whether therapeutically important molecular alterations in NSCLC augment the prognostic information of TNM staging is unclear. To study this, we analyzed molecular data from the ninth edition of the lung cancer staging system.
View Article and Find Full Text PDF